Despite decades of global effort, malaria remains one of the most persistent health challenges in Africa. As of 2026, the WHO African Region still bears approximately 95% of global malaria cases and deaths, with children under five accounting for the vast majority of these losses.
At Atome Pharma Group, we recognize that malaria isn’t just a medical issue; it is a logistical and accessibility challenge. Here is how we are working to turn the tide.
The Burden in Numbers
The statistics remain a call to action for every stakeholder in the pharmaceutical industry:
265 million cases: Estimated annual malaria cases in the African region.
Vulnerable Populations: Roughly 75% of all malaria deaths in the region occur in children under five.
Economic Impact: Malaria traps families in a cycle of poverty, costing the continent billions in lost productivity and healthcare expenses every year.
Our Commitment: Bridging the "Last Mile"
A breakthrough medicine in a lab is only effective if it reaches the patient in a remote village. Atome Pharma Group acts as a critical link in this chain. We don't just distribute; we strategically partner with National Malaria Control Programs (NMCP) and international institutions to ensure that high-quality, WHO-prequalified antimalarials are available where they are needed most.
How We Fight Back
Support for Institutional Markets: We provide a "launching platform" for partners to become certified UN suppliers, facilitating the flow of essential medicines into the public sector.
Regulatory Speed: By navigating the complex registration processes in French and English-speaking Africa, we reduce the time it takes for new, more effective treatments to enter the market.
Pharmacovigilance: Patient safety is paramount. We monitor the real-world use of antimalarials to ensure they remain safe and effective against evolving drug-resistant strains.
Local Expertise: With offices in Dakar, Abidjan, and Yaoundé, we understand the local supply chain bottlenecks and work daily to overcome them.
A Future Without Malaria
The road to 2030—the global target for a 90% reduction in malaria—is steep. It requires more than just medicines; it requires a robust, reliable infrastructure that treats healthcare as a human right.
At Atome Pharma, our philosophy remains: Humanity is at the heart of our business. Whether it's through bed net distribution, diagnostic support, or life-saving ACTs (Artemisinin-based Combination Therapies), we are committed to a malaria-free Africa.
Would you like to learn more about our partnerships or our specific geographical reach in West and Central Africa? Explore our Presence or Contact our Team.